Search results for "OUTCOME"

showing 10 items of 5148 documents

From gut microflora imbalance to mycobacteria infection: is there a relationship with chronic intestinal inflammatory diseases?

2011

The gut of a healthy adult harbours a myriad of different microbial species. It is estimated that approximately 10 14 are present in total bacterial colony forming units (CFU). Each colony colonizes a specific intestinal tract. In healthy adult, the main control of intestinal bacterial colonization occurs through gastric acidity but also other factors can influence the intestinal microenvironment such as pH, temperature, competition among different bacterial strains, peristalsis, drugs, radiotherapy and much more. Impaired microbial homeostasis leads to an alteration of the permeability of tissue, together with the activation of the intestinal immune system MALT (mucosal associated lymphoid…

Settore MED/07 - Microbiologia E Microbiologia ClinicaProbioticsMycobacterium Infections NontuberculousNontuberculous MycobacteriaInflammatory Bowel DiseasesSettore MED/18 - Chirurgia GeneraleTreatment OutcomeCrohn DiseaseRisk FactorsChronic DiseaseHumansColitis Ulcerativeintestinal microflora imbalance intestinal immune system chronic intestinal diseases mycobacteria probioticsIntestinal MucosaAnnali italiani di chirurgia
researchProduct

A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort.

2022

ODYSSEY APPRISE trial evaluated efficacy and safety of alirocumab in 994 patients with hypercholesterolemia and high CV risk in a real-life setting. The aim of the present report is to detail on the Italian cohort enrolled and treated in the trial.The methodology of the of the multinational, single-arm, Phase 3b open-label ODYSSEY APPRISE (Clinicaltrials.gov: NCT02476006) has been previously reported. 255 Italian patients were enrolled and treated according to the trial protocol. Overall mean exposure to alirocumab was 83.3 ± 27.7 weeks. At week 12, LDL-C decreased by 51.3 ± 23.1% and this reduction was overall maintained for the duration of the study. A similar reduction was observed in pa…

Settore MED/09 - Medicina InternaNutrition and DieteticsLDL-C.Endocrinology Diabetes and MetabolismAnticholesteremic AgentsMedicine (miscellaneous)alirocumabCholesterol LDLAntibodies Monoclonal HumanizedHyperlipoproteinemia Type IIheterozygous familial hypercholesterolemiaTreatment OutcomeItalyHumansheterozygous familial hypercholesterolemia; high cardiovascular risk; alirocumab; LDL-C; Italyhigh cardiovascular riskCardiology and Cardiovascular MedicineLDL-CNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-co…

2022

Background and aims: The LISTEN trial (ClinicalTrial.gov accession: NCT01950884) is a phase IV 52 weeks double blind parallel randomized controlled trial that evaluated the effect of ezetimibe plus lifestyle and dietary intervention (eze) vs. lifestyle and dietary intervention alone (placebo) on progression and complications of non-alcoholic steatohepatitis (NASH) evaluated by liver histology. Methods and results: Forty patients with NASH ascertained by histology were randomly allocated on the two study groups and subjected to a follow-up of 52 weeks, when they underwent a second liver biopsy. Main composite end point (EP) was based on the histological improvement in the severity of NASH. T…

Settore MED/12 - GastroenterologiaNutrition and DieteticsSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismBiopsyMedicine (miscellaneous)Liver biopsyEzetimibeTreatment OutcomeDouble-Blind MethodRandomized controlled trialNon-alcoholic Fatty Liver DiseaseHumansCardiology and Cardiovascular MedicineNon-alcoholic steatohepatitiLife StyleNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

2023

Background and aims: Severe liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER cohort, the long-term HCC risk profile based on predictors monitored after HCV eradication by direct-acting antivirals in patients with cirrhosis. Methods: HCC occurrence was evaluated by Kaplan-Meier analysis. Cox regression analysis identified the post-treatment variables associated with de-novo HCC; their predictive power was presented in a nomogram. Results: After the end of therapy (median follow-up:28.47 months), among 2064 SVR patients, 119 (5.8%) developed de-novo HCC. The HCC incidence was 1.90%, 4.21%, 6.47% a…

Settore MED/12Real-life cohort.HepatologyDirect-acting antiviral; HCC; Long term outcomes; Predictive factors; Real-life cohortGastroenterologyReal-life cohortLong term outcomeHCCPredictive factorDirect-acting antiviralLong term outcomesPredictive factors
researchProduct

MATURE AND IMMATURE TERATOMA: RESULTS OF THE FIRST PEDIATRIC ITALIAN STUDY ITALIAN

2007

Abstract Teratoma is the most common germ cell tumour in childhood; mature (MT) and immature teratomas (IT) are benign tumours, but if they recur, they can be in some cases malignant. The aim of this paper is to evaluate Italian patients with MT and IT enrolled from 1991 to 2001, in a prospective multicentric study. One hundred and eighty-three patients, observed in 15 Italian Centers of Paediatric Oncology and three Paediatric Surgical Units were enrolled. Clinical data, treatment and results were all analysed. Initial evaluation and subsequent follow up included clinical examination, tumour markers and imaging procedures. Surgical resection was recommended for all the tumours. Histology w…

Settore MED/20 - Chirurgia Pediatrica E InfantileMature teratoma Immature teratoma Childhood tumours Treatment and outcome
researchProduct

Il “costo standard unitario di formazione per studente in corso” a supporto della progettazione delle politiche e strategie accademiche secondo una p…

2016

La recente introduzione del “costo standard di formazione per studente in corso” quale criterio per la valutazione ministeriale degli atenei impone un profondo ripensamento delle metodologie e degli schemi sottostanti alla progettazione dei sistemi di governo e di misurazione della performance adottati all’interno delle università italiane. Tale ripensamento deve essere esteso – attraverso una prospettiva sistemica – anche alla valutazione delle attività di Terza Missione che producono un impatto sul territorio di riferimento. Con l’obiettivo di supportare l’attività di diagnosi e la successiva ridefinizione delle politiche e strategie delle istituzioni accademiche, il presente studio mira …

Settore SECS-P/07 - Economia AziendaleCosto standard performance management università output outcome
researchProduct

La misurazione della performance accademica: un'analisi applicata al "costo standard per studente in corso"

2017

The recent introduction of the “standard cost per regular student”, as a criterion adopted by the Italian Ministry of Education to measure public university performance, implies a deep afterthought of those methods underlying the design of performance management and measurement systems in Italian universities. This has also to be extended – through a systemic perspective – to the evaluation of the Third Mission activities influencing the corresponding socio-economic context. With the intent to support a diagnostic activity related to the academic performance, this paper aims at introducing a system of output-outcome indicators – within a consistent framework – oriented to measure the driver…

Settore SECS-P/07 - Economia AziendaleProspettiva bilanciata 'output-outcome'Misurazione performance accademicaUniversitàStandard Unit Cost to Educate a Regular StudentOutput-to-Outcome ManagementPerformance IndicatorsCosto standard per studente in corso
researchProduct

Looking at the impact of collaborative policies on intangibles and outcomes through dynamic performance governance

2023

The Etorkizuna Eraikiz (EE) case study provides thought-provoking insights on the role of intangibles as driving forces for a collaborative network governance primarily lead by the civil society. Among such factors are: 1) social cohesion around core values rooted in cultural traditions (e.g. language and gastronomy); 2) natural and historical assets; 3) human and social capital; and 4) policy innovation. All of them are at the same time framed in an ideal continuity with history, and consistently transposed into the future (Bianchi et al., 2019, p. 104). The fast and intensive growth in both the collaborative network and the achieved outcomes experienced since the inception of the EE ‘mode…

Settore SECS-P/07 - Economia AziendaleUncertaintyDynamic Performance GovernanceCollaborative GovernanceOutcome
researchProduct

Declines in Sexual Activity and Function Predict Incident Health Problems in Older Adults: Prospective Findings from the English Longitudinal Study o…

2020

The objective of this study was to investigate cross-sectional and longitudinal associations between declines in sexual activity and function and health outcomes in a large population-based sample of older adults. Data were from 2577 men and 3195 women aged ≥ 50 years participating in the English Longitudinal Study of Ageing. Past-year changes in sexual desire, frequency of sexual activity, and ability to have an erection (men)/become sexually aroused (women) were assessed at baseline by self-completion questionnaire. Health outcomes (self-rated health, limiting long-standing illness, doctor-diagnosed diseases of the vascular system, and cancer) were self-reported at baseline (2012/2013) an…

Sexual activity050103 clinical psychologymedicine.medical_specialtyLongitudinal studyHealth outcomeSexual functionLogistic regressionOdds03 medical and health sciencesArts and Humanities (miscellaneous)medicineErectile dysfunction0501 psychology and cognitive sciencesOlder adultErectile dysfunction Health outcomes Older adults Sexual activity Sexual functionGeneral PsychologyOriginal Paper030505 public healthPublic health05 social sciencesHealth outcomesmedicine.diseaseSexual desireErectile dysfunctionAgeingOlder adultsSexual function.0305 other medical scienceSexual functionPsychologyDemographyArchives of Sexual Behavior
researchProduct

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1)…

2014

Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological response (SVR) in treatment-naive and treatment-experienced patients infected with hepatitis C virus (HCV) genotype 1, the regimens have a high pill burden and are associated with increased rates and severity of adverse events, such as anaemia and rash. The efficacy and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection.In QUEST-1, a phase 3, randomise…

SimeprevirAdultMalemedicine.medical_specialtyGenotypeHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyAntiviral AgentsDrug Administration ScheduleTelaprevirPolyethylene Glycolschemistry.chemical_compoundDouble-Blind MethodPegylated interferonSimeprevirBoceprevirInternal medicineRibavirinmedicineHumanschronic hepatitis CSulfonamidesbusiness.industryRibavirinvirus diseasesInterferon-alphaGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryDrug Therapy CombinationFemalebusinessHeterocyclic Compounds 3-Ringmedicine.drugPeginterferon alfa-2a
researchProduct